Ironwood Pharmaceuticals (IRWD) Scheduled to Post Earnings on Thursday

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) will be issuing its quarterly earnings data before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of $0.08 per share for the quarter. Parties interested in registering for the company's conference call can do so using this link.

Ironwood Pharmaceuticals Price Performance

Shares of IRWD traded down $0.16 during trading hours on Thursday, hitting $3.99. 769,002 shares of the stock were exchanged, compared to its average volume of 2,975,317. Ironwood Pharmaceuticals has a fifty-two week low of $3.79 and a fifty-two week high of $15.70. The business has a 50-day moving average of $4.38 and a 200-day moving average of $5.76. The firm has a market capitalization of $624.55 million, a P/E ratio of -0.60 and a beta of 0.48.

Insider Activity at Ironwood Pharmaceuticals

In related news, insider Minardo John sold 9,910 shares of the firm's stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $4.27, for a total transaction of $42,315.70. Following the transaction, the insider now directly owns 284,661 shares of the company's stock, valued at $1,215,502.47. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 12.90% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Capital One Financial lowered shares of Ironwood Pharmaceuticals from an "overweight" rating to an "equal weight" rating and cut their target price for the stock from $12.00 to $4.00 in a research note on Thursday, August 8th. Craig Hallum cut their target price on shares of Ironwood Pharmaceuticals from $14.00 to $10.00 and set a "buy" rating on the stock in a research note on Friday, August 9th. Leerink Partnrs raised shares of Ironwood Pharmaceuticals to a "hold" rating in a research note on Monday, September 9th. Wells Fargo & Company dropped their price objective on shares of Ironwood Pharmaceuticals from $14.00 to $12.00 and set an "overweight" rating on the stock in a research note on Friday, August 9th. Finally, Leerink Partners assumed coverage on shares of Ironwood Pharmaceuticals in a research note on Monday, September 9th. They issued a "market perform" rating and a $5.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, Ironwood Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $12.17.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.